Chandler Robinson - Sep 30, 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role: Chief Executive Officer, Director
Signature: /s/ Quan Vu, Attorney-in-fact
Stock symbol: MNPR
Transactions as of: Sep 30, 2025
Transactions value $: -$216,099
Form type: 4
Date filed: 10/2/2025, 03:04 PM
Previous filing: Jul 16, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Robinson Chandler	Chief Executive Officer, Director	1000 SKOKIE BLVD SUITE 350, WILMETTE	/s/ Quan Vu, Attorney-in-fact	2025-10-02	0001727334

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MNPR	Common Stock	Options Exercise		+8.73K	+11.88%		82.2K	Sep 30, 2025	Direct	F1
transaction	MNPR	Common Stock	Tax liability	-$216K	-2.65K	-3.22%	$81.67	79.6K	Sep 30, 2025	Direct	F2
holding	MNPR	Common Stock						272K	Sep 30, 2025	See Footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MNPR	Restricted Stock Units	Options Exercise	$0	-8.73K	-10.73%	$0.00	72.6K	Sep 30, 2025	Common Stock	8.73K		Direct	F1, F4, F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares acquired on vesting and settlement of restricted stock units.
F2	Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
F3	As a manager of Tactic Pharma LLC, Dr. Robinson may be deemed to share voting and dispositive power over these 272,026 shares. Dr. Robinson disclaims beneficial ownership of the 272,026 shares held by Tactic Pharma LLC, except to the extent of his pecuniary interest therein.
F4	On February 2, 2022, the reporting person was granted 31,905 restricted stock units, vesting 6/48ths (3,988 shares) on June 30, 2022, and 3/48ths (1,994 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F5	On February 1, 2023, the reporting person was granted 33,803 restricted stock units, vesting 6/48ths (4,225 shares) on June 30, 2023, and 3/48ths (2,113 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
F6	On March 4, 2025, the reporting person was granted 79,899 restricted stock units of which 6,002 shares vested immediately as of the grant date. The remaining 73,897 restricted stock units vest 6/48ths (9,237 shares) on June 30, 2025, and 3/48ths (4,619 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.